In a previous study, high-serum VEGF levels were correlated with poor clinical outcomes in patients with melanoma treated with anti-CTLA-4 antibodies, and patients with high-serum VEGF levels had a significantly lower rate of disease control [16]. The gene discussed is CTLA4; the disease is melanoma.